You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances therapeutic efficacy while mitigating the debilitating side
- 2. The role of cytostatic in oxidative stress reactions
- 3. Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
- 4. Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- 5. 9Prostate cancer screening urgently needed, says Rishi Sunak
- 6. Multimodal integration of [18F]PSMA-1007 PET/CT semiquantitative parameters and clinicopathological data for predicting prostate cancer metastasis
- 7. Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
- 8. Effects of Dexmedetomidine Nasal Sprays on Postoperative Sleep Quality in Patients Who Underwent Laparoscopic Gynaecological Surgery: A Single-Centre, Double-Blind, Randomized Controlled Study
- 9. Rosai-Dorfman disease mimicking lung cancer: a case report
- 10. Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review
Last updated at 19:27 GMT
Hot News Makers
Health/Pharma Companies
-
26266.27
-
15760.51
-
13221.30
-
13069.69
-
12316.37
-
10666.86
-
9140.02
-
8572.71
-
7968.23
-
7227.00
Drugs, Treatments, Trials
-
15040.01
-
10483.86
-
9959.67
-
8731.98
-
7316.39
-
6085.24
-
5761.67
-
5457.49
-
3809.39
-
2476.49
Last updated at 19:10 GMT
